2. Amyotrophic lateral sclerosis Disease details / Clinical trials / Drug dev / DR info

(2R)-2-Propyloctanoic acid
   ONO Pharmaceutical Co., Ltd.
      2008   Phase 2   EUCTR2007-004723-37-FR   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-GB   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-DE   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-BE   Belgium;France;Germany;United Kingdom;
   ONO Pharmaceutical Co.,Ltd
      2007   -   EUCTR2006-002660-26-NL   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2007   -   EUCTR2006-002660-26-GB   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   Phase 2   EUCTR2006-002660-26-FR   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-DE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-BE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-AT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
(6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate
   Biogen Idec Limited
      2011   Phase 3   EUCTR2010-022818-19-ES   Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
(R)-(-)-2-Propyloctaroic acid
   ONO PHARMA UK LTD
      2004   -   EUCTR2004-002912-27-ES   Spain;
201600930
   The University of Queensland
      2021   Phase 2   EUCTR2020-005018-17-NL   Australia;Netherlands;
3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one.
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
3K3A-APC Protein
   Macquarie University, Australia
      2021   Phase 2   NCT05039268   Australia;
4 cholesten-3-one, oxime
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom;
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
4-cholesten-3-one, oxime
   TROPHOS
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom;
   TROPHOS SA
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom;
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom;
6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
   CYTOKINETICS, INC.
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
   Cytokinetics Inc
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
   Retrotope, Inc.
      2021   Phase 2   EUCTR2020-003962-38-SE   Estonia;Netherlands;Sweden;
      2021   Phase 2   EUCTR2020-003962-38-NL   Estonia;Netherlands;Sweden;
      2021   Phase 2   EUCTR2020-003962-38-EE   Estonia;Netherlands;Sweden;
AB 1003
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
AB1010
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2010-024423-24-IT   Argentina;Colombia;France;Germany;Greece;Hungary;Italy;Mexico;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;
   AB Science
      2022   Phase 3   EUCTR2019-001862-13-GR   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001862-13-DK   Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-PL   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001862-13-IE   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001862-13-GB   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
   ABScience
      2022   Phase 3   EUCTR2019-001862-13-PT   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001862-13-NO   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-SI   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-SE   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-PT   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-NL   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-HU   Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-GR   Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2010-024423-24-SK   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-024423-24-ES   France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
ABBV-CLS-7262
   Calico Life Sciences LLC
      2021   Phase 1   NCT04948645   Canada;United States;
ACIDO TAUROURSODESOSSICOLICO
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
AL001
   Alector Inc.
      2021   Phase 2   NCT05053035   United States;
ALPHA-LIPOIC ACID
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2006   -   EUCTR2005-005152-40-IT   Italy;
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-004619-30-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Alexion Pharmaceuticals
      2020   Phase 3   EUCTR2019-004619-30-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
ALZT-OP1a (cromolyn)
   AZTherapies, Inc.
      2020   Phase 2   NCT04428775   United States;
AMSC
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic;
AMX0035
   AMYLYX PHARMACEUTICALS Inc.
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   Amylyx Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   -   NCT05286372   -
      2021   Phase 3   NCT05021536   Puerto Rico;United States;
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2/Phase 3   NCT04516096   United States;
      2018   Phase 2   NCT03488524   United States;
      2017   Phase 2/Phase 3   NCT03127514   United States;
ANX005
   Annexon Biosciences
      2021   Phase 2   EUCTR2021-000325-26-FR   Canada;France;United States;
   Annexon, Inc.
      2021   Phase 2   NCT04569435   Canada;France;United States;
AP-101
   AL-S Pharma
      2021   Phase 2   NCT05039099   Canada;Germany;Korea, Republic of;Sweden;United States;
      2019   Phase 1   NCT03981536   Canada;
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2019-003797-10-IT   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
   Apellis Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2019-003797-10-NL   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-003797-10-IE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-003797-10-DE   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2019-003797-10-CZ   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
APO-P001
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden;
AT-1501
   Anelixis Therapeutics, LLC
      2020   Phase 2   NCT04322149   Canada;United States;
AVP-923
   Avanir Pharmaceuticals
      2001   Phase 3   NCT00021697   United States;
AZILECT® 1 mg Tabletten
   Universitätsklinikum Ulm
      2013   Phase 2   EUCTR2011-004482-32-DE   Germany;
Abacavir
   Stichting TRICALS Foundation
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Netherlands;United Kingdom;
Acetylcarnitine
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2005   -   EUCTR2004-004158-23-IT   Italy;
Acthar
   Mallinckrodt
      2017   Phase 2/Phase 3   NCT03068754   Argentina;Canada;Chile;Colombia;Mexico;Peru;United States;
Actos
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany;
Albumin
   Instituto Grifols, S.A.
      2014   Phase 2   NCT02479802   Spain;
Albutein
   Grifols Therapeutics LLC
      2016   Phase 2   NCT02872142   United States;
   Instituto Grifols S.A.
      2014   Phase 4   EUCTR2013-004842-40-ES   Spain;
Albúmina humana
   Instituto Grifols S.A.
      2014   Phase 4   EUCTR2013-004842-40-ES   Spain;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine
   Ionis Pharmaceuticals, Inc.
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-
   IONIS PHARMACEUTICALS, INC.
      -   Phase 1;Phase 3   EUCTR2020-005522-28-IT   Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
AlloRx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05003921   Antigua and Barbuda;
Amivita
   Wujin People's Hospital
      2017   -   NCT03103815   China;
Anakinra
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01277315   Germany;
Arimoclomol
   CytRx
      2008   Phase 2   NCT00561366   Canada;United States;
      2005   Phase 2   NCT00244244   United States;
   Orphazyme
      2019   Phase 3   NCT03836716   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   NCT03491462   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   University of Miami
      2009   Phase 2/Phase 3   NCT00706147   United States;
AstroRx
   Kadimastem
      2018   Phase 1/Phase 2   NCT03482050   Israel;
Autologous Adipose-derived Mesenchymal Stromal Cells
   Mayo Clinic
      2017   Phase 2   NCT03268603   United States;
Autologous MSC-NTF cells
   Brainstorm-Cell Therapeutics
      2014   Phase 2   NCT02017912   United States;
Autologous Mesenchymal stem cells (MSCs)
   Hospital e Maternidade Dr. Christóvão da Gama
      2015   Phase 1   NCT02987413   Brazil;
Autologous T-regulatory lymphocytes
   Stanley H. Appel, MD
      2016   Phase 1   NCT03241784   United States;
Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded
   Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
      2019   Phase 2   EUCTR2019-002302-46-ES   Spain;
Autologous adult bone marrow mononuclear cells unexpanded
   Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
      2019   Phase 2   EUCTR2019-002302-46-ES   Spain;
Autologous bone marrow mononucleated cells
   Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
      2014   -   EUCTR2011-004801-25-ES   Spain;
Autologous bone marrow-derived stem cells
   TCA Cellular Therapy
      2010   Phase 1   NCT01082653   United States;
Autologous mesenchymal stem cells
   Mayo Clinic
      2012   Phase 1   NCT01609283   United States;
      2010   Phase 1   NCT01142856   United States;
BHV-0223
   Biohaven Pharmaceuticals, Inc.
      2018   Phase 1   NCT03520517   United States;
BIIB050 / KNS-760704
   Biogen Idec Limited
      2011   Phase 3   EUCTR2010-022818-19-ES   Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-022818-19-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-SE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-NL   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-IE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-GB   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-DE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB050/KNS-760704
   Biogen Idec Research Limited
      2012   Phase 3   EUCTR2011-006119-70-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-NL   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-IE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-GB   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-ES   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB067
   Biogen
      2017   Phase 3   NCT03070119   Belgium;Canada;France;Germany;Italy;Japan;New Zealand;United Kingdom;United States;
      2016   Phase 3   NCT02623699   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
BIIB067 (ISIS666853)
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2020-004590-51-IT   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2016-003225-41-IT   Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States;
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-FR   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004590-51-ES   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004590-51-DE   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2016-003225-41-ES   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2016-003225-41-PL   Argentina;Australia;Belgium;Canada;Denmark;European Union;Germany;Japan;Korea, Republic of;Poland;United Kingdom;United States;
      2020   Phase 3   EUCTR2016-003225-41-DK   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2015-004098-33-PL   Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
      2020   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003225-41-DE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003225-41-BE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2017   Phase 1;Phase 3   EUCTR2016-003225-41-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-SE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-GB   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-BE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
BIIB067 (Tofersen)
   Biogen
      2021   Phase 3   NCT04856982   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
BIIB078
   Biogen
      2020   Phase 1   NCT04288856   Canada;Netherlands;Switzerland;United Kingdom;United States;
      2018   Phase 1   NCT03626012   Canada;Ireland;Netherlands;Switzerland;United Kingdom;United States;
BIIB100
   Biogen
      2019   Phase 1   NCT03945279   United States;
BIIB105
   Biogen
      2020   Phase 1   NCT04494256   Canada;Italy;Netherlands;United States;
BLZ945
   Novartis Pharma AG
      2019   Phase 2   EUCTR2019-000826-22-SE   Finland;Sweden;United States;
      2019   Phase 2   EUCTR2019-000826-22-FI   Finland;Sweden;United States;
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04066244   Finland;Sweden;United States;
BOTOX 100 UNITES ALLERGAN (PR1)
   Hospices Civils de Lyon
      2011   Phase 2   EUCTR2010-023161-21-FR   France;
BRX-345
   ORPHAZYME APS
      2019   Phase 3   EUCTR2019-000374-39-IT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-IT   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000374-39-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000374-39-PL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000374-39-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000374-39-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000374-39-ES   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000374-39-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-SE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-PL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-NL   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-GB   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-FR   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-ES   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000137-13-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Baclofen
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy;
Barium
   Milton S. Hershey Medical Center
      2022   -   NCT04889898   United States;
Basiliximab
   Emory University
      2013   Phase 2   NCT01884571   United States;
Beta Hydroxybutyrate
   University of Ulm
      2021   Phase 2   NCT04820478   Germany;
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
   Edward Kasaraskis
      2017   Early Phase 1   NCT03707795   United States;
Biotin
   American University of Beirut Medical Center
      2018   Phase 2   NCT03427086   Lebanon;
Blood sample and environmental survey
   Centre Hospitalier Universitaire de Pointe-a-Pitre
      2014   -   NCT03367650   Guadeloupe;Martinique;
Bosutinib
   Center for iPS Cell Research and Application, Kyoto University
      2019   Phase 1   JPRN-UMIN000036295   Japan;
   Inoue Haruhisa
      2019   Phase 1   JPRN-jRCT2051190001   Japan;
   Kyoto University
      2019   Phase 1   NCT04744532   Japan;
Botox injection
   Hospices Civils de Lyon
      2012   Phase 2   NCT01551940   France;
Botulinum toxin type B (Myobloc)
   The University of Texas Health Science Center at San Antonio
      2003   Phase 2/Phase 3   NCT00125203   United States;
Butylphthalide
   Peking Union Medical College Hospital
      2015   -   ChiCTR-IPR-15007365   China;
CARBOLITHIUM
   I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
      2007   -   EUCTR2007-002379-16-IT   Italy;
   ISTITUTO SUPERIORE DI SANITA`
      2009   -   EUCTR2008-006722-34-IT   Italy;
CARBOLITHIUM*100CPS
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2008   -   EUCTR2008-001094-15-IT   Italy;
CC100
   Chemigen, LLC
      2017   Phase 1   NCT03049046   United States;
CK-2017357
   CYTOKINETICS, INC.
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
   Cytokinetics
      2012   Phase 2   NCT01709149   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2011   Phase 2   NCT01486849   United States;
      2010   Phase 2   NCT01089010   United States;
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
CK-2017357 (Part A)
   Cytokinetics
      2011   Phase 2   NCT01378676   United States;
CK-2017357 (Part B)
   Cytokinetics
      2011   Phase 2   NCT01378676   United States;
CK-2127107
   CYTOKINETICS, INC.
      2021   Phase 3   EUCTR2020-004040-29-IT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Cytokinetics Inc
      2022   Phase 3   EUCTR2020-004040-29-PT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004040-29-SE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004040-29-NL   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004040-29-IE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004040-29-ES   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004040-29-FR   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004040-29-DE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004040-29-BE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Cytokinetics, Inc.
      2018   Phase 2   EUCTR2018-000586-37-NL   Australia;Canada;Ireland;Netherlands;Spain;United States;
      2018   Phase 2   EUCTR2018-000586-37-IE   Australia;Canada;Ireland;Netherlands;Spain;United States;
      2018   Phase 2   EUCTR2018-000586-37-ES   Australia;Canada;Ireland;Netherlands;Spain;United States;
CK2017357
   Cytokinetics Inc
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
CNM-Au8
   Clene Nanomedicine
      2022   -   NCT05281484   United States;
      2019   Phase 2   NCT04098406   Australia;
      2019   -   NCT04081714   United States;
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04414345   United States;
      2020   Phase 2/Phase 3   NCT04297683   United States;
COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
      2018   Phase 2   EUCTR2017-004459-21-IT   Italy;
Caffeine
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States;
Calogen
   University of Ulm
      2015   -   NCT02306590   Germany;
Cannabis Sativa extract Oromucosal spray
   Ospedale San Raffaele
      2013   Phase 2/Phase 3   NCT01776970   Italy;
Cannabis, Medical
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Capsaicin
   University of Florida
      2016   Early Phase 1   NCT02710162   United States;
      2016   Early Phase 1   NCT02710110   United States;
Capsaicin Challenge
   University of Florida
      2017   -   NCT02962050   United States;
Carbidopa-levodopa
   Washington University School of Medicine
      2019   Phase 1   NCT03929068   United States;
Carbonate de lithium
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-003707-32-FR   France;
Ceftriaxone
   AZIENDA OSPEDALIERA PISANA
      2007   -   EUCTR2007-004165-17-IT   Italy;
   Massachusetts General Hospital
      2006   Phase 3   NCT00349622   Canada;Puerto Rico;United States;
Celecoxib
   Columbia University
      2006   Phase 2   NCT00355576   United States;
Cell-based therapeutics
   Pomeranian Medical University Szczecin
      2010   Phase 1   NCT02193893   Poland;
Cell-based therapy
   University of Warmia and Mazury
      2015   Phase 1   NCT02881489   -
      2015   Phase 1   NCT02881476   -
Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
   Mossakowski Medical Research Centre Polish Academy of Sciences
      2015   Phase 1   NCT03296501   Poland;
Cimetidine plus Dexpramipexole
   Knopp Biosciences
      2012   Phase 1   NCT01536249   United States;
Cistanche Total Glycosides
   Peking University
      2008   Phase 2   NCT00753571   China;
Clenbuterol
   Dwight Koeberl, M.D., Ph.D.
      2020   Phase 2   NCT04245709   United States;
Coenzyme Q10
   Columbia University
      2005   Phase 2   NCT00243932   United States;
Colchicine 1 MG Oral Tablet
   Azienda Ospedaliero-Universitaria di Modena
      2019   Phase 2   NCT03693781   Italy;
Combination Product: Active treatment with dual therapy
   El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
      2016   Phase 2   NCT03204500   Mexico;
Control group
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   -   NCT04518540   China;
Copegus
   Apodemus AB
      2014   Phase 2   EUCTR2012-002099-15-SE   Sweden;
Creatine
   Columbia University
      2006   Phase 2   NCT00355576   United States;
   National Center for Research Resources (NCRR)
      2000   Phase 2   NCT00005674   United States;
   Nazem Atassi
      2011   Phase 2   NCT01257581   United States;
Creatine Monohydrate
   The Avicena Group
      2003   Phase 3   NCT00069186   United States;
Creatine monohydrate
   National Center for Complementary and Integrative Health (NCCIH)
      2002   Phase 2   NCT00070993   United States;
Creatinine
   National Center for Research Resources (NCRR)
      2000   Phase 2   NCT00005766   United States;
Cu(II)ATSM
   Collaborative Medicinal Development Pty Limited
      2020   Phase 2   NCT04313166   Australia;
      2019   Phase 2/Phase 3   NCT04082832   Australia;
      2018   Phase 1/Phase 2   NCT03136809   Australia;
      2016   Phase 1   NCT02870634   Australia;
Células Mesenquimales de tejido adiposo
   FUNDACIÓN PROGRESO Y SALUD
      2013   -   EUCTR2011-006254-85-ES   Spain;
Células madre mesenquimales de tejido adiposo autólogo
   FUNDACIÓN PROGRESO Y SALUD
      2013   -   EUCTR2011-006254-85-ES   Spain;
Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea
   Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
      2014   -   EUCTR2011-004801-25-ES   Spain;
DEXTRAN SULFATE SODIUM
   TikoMed AB
      2018   Phase 2   EUCTR2017-005065-47-SE   Sweden;
DNL343
   Denali Therapeutics Inc.
      2021   Phase 1   NCT05006352   Netherlands;United States;
DNL747
   Sanofi
      2018   Phase 1   NCT03757351   Netherlands;United States;
Daraprim
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States;
Darunavir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States;
Deferiprone
   University Hospital, Lille
      2019   Phase 2/Phase 3   NCT03293069   France;
      2013   Phase 2   NCT02164253   France;
      2011   -   NCT02880033   France;
Deferiprone DR
   centre hospitalier universitaire de Lille
      2018   Phase 3   EUCTR2017-003763-35-FR   France;
Dexdor
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland;
Dexpramipexole
   Biogen Idec Limited
      2011   Phase 3   EUCTR2010-022818-19-ES   Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
   Biogen Idec Research Limited
      2012   Phase 3   EUCTR2011-006119-70-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-NL   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-IE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-GB   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-ES   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-006119-70-DE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
   Knopp Biosciences
      2012   Phase 3   NCT01622088   Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2012   Phase 1   NCT01511029   United States;
      2011   Phase 3   NCT01281189   Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 1   NCT01449578   United States;
Dexpramipexole (dose 1)
   Knopp Biosciences
      2011   Phase 1   NCT01424176   United States;
Dexpramipexole (dose 2)
   Knopp Biosciences
      2011   Phase 1   NCT01424176   United States;
Dexpramipexole Dichydrochloride
   Biogen Idec Limited
      2011   Phase 3   EUCTR2010-022818-19-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-SE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-NL   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-IE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-022818-19-GB   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dexpramipexole Dihydrochloride
   Biogen Idec Limited
      2011   -   EUCTR2010-022818-19-DE   Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS)
   University of Birmingham
      2018   Phase 2   EUCTR2018-000668-28-GB   United Kingdom;
Dextromethorphan HBr and quinidine sulfate
   University of Florida
      2019   Phase 1/Phase 2   NCT03883581   United States;
Dextromethorphan hydrobromide 20 mg and quinidine sulfate
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States;
Dextromethorphan hydrobromide 30 mg and quinidine sulfate
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States;
Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
   Milton S. Hershey Medical Center
      2022   -   NCT04889898   United States;
Dolutegravir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States;
   Stichting TRICALS Foundation
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Netherlands;United Kingdom;
Dronabinol
   Cantonal Hospital of St. Gallen
      2005   -   NCT00812851   Switzerland;
Dutasterida
   Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
      2021   Phase 2   EUCTR2021-001989-38-ES   Spain;
E0302 (mecobalamin)
   Eisai Co., Ltd.
      2008   Phase 2/Phase 3   NCT00445172   Japan;
      2007   Phase 2/Phase 3   NCT00444613   Japan;
EBIXA
   Jorge Matias-Guiu Guia
      2008   -   EUCTR2007-002117-39-ES   Spain;
EH301 (Nicotinamide Riboside/Pterostilbene)
   Haukeland University Hospital
      2020   -   NCT04562831   Norway;
EPI-589
   Fujita Koji
      2021   Phase 2   JPRN-jRCT2061210031   Japan;
   Hamatani Tatsuto
      2021   Phase 1   JPRN-jRCT2071210023   Japan;
      2018   Phase 1   JPRN-jRCT2071210022   Japan;
   PTC Therapeutics
      2016   Phase 2   NCT02460679   United States;
EPREX IV SC 1FL 1ML 40000 UI
   ISTITUTO NEUROLOGICO CARLO BESTA
      2005   -   EUCTR2005-005873-31-IT   Italy;
EPREX*1SIR 40000UI/ML 1ML
   ISTITUTO NEUROLOGICO CARLO BESTA
      2011   -   EUCTR2011-001329-26-IT   Italy;
      2010   -   EUCTR2009-016066-91-IT   Italy;
Edaravone
   Ehime University Hospital
      2015   Phase 1,2   JPRN-UMIN000016352   Japan;
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
   Ferrer Internacional, S.A.
      2021   Phase 3   EUCTR2020-003376-40-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03272802   Iran, Islamic Republic of;
   Kondo Kazuoki
      2022   Phase 3   JPRN-jRCT2071210117   Canada;Germany;Italia;Japan;South Korea;Switzerland;US;
      2021   Phase 3   JPRN-jRCT2031200301   Canada;France;Germany;Italy;Japan;Korea;Switzerland;United States of America;
      2021   Phase 1   JPRN-jRCT2031200361   Japan;
      2020   Phase 3   JPRN-jRCT2041200084   Canada;France;Germany;Italy;Japan;United States of America;
   Mitsubishi Tanabe Development America Inc.
      2021   Phase 3   EUCTR2019-004256-11-IT   Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
      2020   Phase 3   EUCTR2019-002108-41-IT   Canada;France;Germany;Italy;Japan;United States;
   Mitsubishi Tanabe Pharma America Inc.
      2019   -   NCT04259255   Canada;United States;
   Okayama university
      2016   -   JPRN-UMIN000024854   Japan;
Electrical Impedance Myography
   University of Florida
      2016   Early Phase 1   NCT02710162   United States;
Endocannabinoid palmitoylethanolamide (PEA)
   University of Roma La Sapienza
      2014   -   NCT02645461   -
Engensis
   Helixmith Co., Ltd.
      2021   Phase 2   NCT04632225   Korea, Republic of;United States;
Enoxacin
   McGill University
      2021   Phase 1/Phase 2   NCT04840823   Canada;
Eril®
   Georg-August-Universität Göttingen
      2019   Phase 2   EUCTR2017-003676-31-FR   France;Germany;Switzerland;
Erythropoetin (EPO)
   University Hospital Muenster
      2006   Phase 2   NCT00298597   Germany;
Erythropoietin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2005   -   EUCTR2005-005873-31-IT   Italy;
   ISTITUTO NEUROLOGICO CARLO BESTA
      2010   -   EUCTR2009-016066-91-IT   Italy;
Escitalopram
   University of South Carolina
      2009   Phase 3   NCT00965497   United States;
Ezogabine
   Brian Wainger
      2015   Phase 2   NCT02450552   United States;
F 18 T807
   Tammie L. S. Benzinger, MD, PhD
      2015   -   NCT02414230   United States;
FAB122
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
   Ferrer Internacional, S.A.
      2022   Phase 3   EUCTR2020-003376-40-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003376-40-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003376-40-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003376-40-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
      2021   Phase 3   EUCTR2020-003376-40-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003376-40-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
FASUDIL HYDROCHLORIDE
   Georg-August-Universität Göttingen
      2019   Phase 2   EUCTR2017-003676-31-FR   France;Germany;Switzerland;
FLX-787-ODT
   Flex Pharma, Inc.
      2018   Phase 1/Phase 2   NCT03334786   United States;
FLX-787-ODT (orally disintigrating tablet)
   Flex Pharma, Inc.
      2017   Phase 1/Phase 2   NCT03338114   United States;
FamC-1
   Polski Bank Komórek Macierzystych JSC (PBKM)
      2020   Phase 1;Phase 2   EUCTR2018-004171-12-PL   Poland;
Fasudil
   Peking University Third Hospital
      2013   Phase 2   NCT01935518   China;
   University Medical Center Goettingen
      2019   Phase 2   NCT03792490   France;Germany;Switzerland;
Fasudil (WP-0512)
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT05218668   Australia;United States;
Febuxostat
   Teikyo University
      2017   -   JPRN-UMIN000029308   Japan;
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Fecal microbiota transplantation
   Azienda Ospedaliero-Universitaria di Modena
      2020   -   NCT03766321   Italy;
Fenilbutirato
   Amylyx Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Fig
   FeGALS
      2009   -   JPRN-UMIN000008527   Japan;
Filgrastim
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of;
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy;
Fixed dose combination Ciprofloxacin/Celecoxib
   NeuroSense Therapeutics Ltd.
      2019   Phase 2   NCT04165850   Israel;
      2019   Phase 1   NCT04090684   United States;
Fycompa
   American University of Beirut Medical Center
      2019   Phase 2   NCT03377309   Lebanon;
G04CB02
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain;
GA
   TEVA Pharmaceutical Industries. Ltd.
      2006   Phase 2   EUCTR2006-001688-49-GB   Belgium;Germany;Italy;United Kingdom;
      2006   -   EUCTR2006-001688-49-DE   Belgium;Germany;Italy;United Kingdom;
      2006   -   EUCTR2006-001688-49-BE   Belgium;Germany;Italy;United Kingdom;
GDC-0134
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States;
GM604
   Genervon Biopharmaceuticals, LLC
      2013   Phase 2   NCT01854294   United States;
GSK1223249
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
   GlaxoSmithKline
      2009   Phase 1   NCT00875446   France;Italy;United Kingdom;United States;
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GUANA2015
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy;
GUANABENZ ACETATO
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy;
Gilenya
   Massachusetts General Hospital
      2013   Phase 2   NCT01786174   United States;
Gold
   Peking Union Medical College Hospita
      2019   -   ChiCTR1900024520   China;
Gold Nanocrystals
   Clene Nanomedicine
      2021   Phase 2   NCT03843710   United States;
Granulocyte - colony stimulating factor (G-CSF)
   University Hospital Muenster
      2006   Phase 2   NCT00298597   Germany;
Granulocyte Colony Stimulating Factor
   Peking University
      2006   Phase 2   NCT00397423   China;
   Tehran University of Medical Sciences
      2012   Phase 2/Phase 3   NCT01825551   Iran, Islamic Republic of;
Growth Hormone (Somatropin)
   Federico II University
      2007   Phase 2   NCT00635960   Italy;
HB-adMSCs
   Hope Biosciences Stem Cell Research Foundation
      2020   -   NCT04514952   United States;
HK-001
   Everfront Biotech Co., Ltd.
      2021   Phase 1   NCT03651349   Taiwan;
HUMAN ALBUMIN SOLUTION
   Instituto Grifols S.A.
      2014   Phase 4   EUCTR2013-004842-40-ES   Spain;
HYNR-CS inj
   Corestem, Inc.
      2011   Phase 1/Phase 2   NCT01363401   Korea, Republic of;
HYNRCS-Allo inj
   Hanyang University Seoul Hospital
      2017   Phase 1   NCT03214146   Korea, Republic of;
Human Neural Stem Cells
   Azienda Ospedaliera Santa Maria, Terni, Italy
      2011   Phase 1   NCT01640067   Italy;
Human autologous mesenchymal stem cells
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic;
Huolingshengji Granules
   Peking University Third Hospital
      2020   Phase 2/Phase 3   NCT04950933   China;
Hyperpolarized [1-13C]pyruvate
   Christoffer Laustsen
      2020   Phase 2   EUCTR2020-000352-36-DK   Denmark;
I-123] ADAM
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France;
IC14
   Implicit Bioscience
      2021   Phase 2   NCT04390386   United States;
      2019   Phase 2   NCT03508453   Australia;
      2019   -   NCT04309604   United States;
      2017   Phase 1   NCT03487263   Australia;
IC14 (monoclonal antibody against human CD14)
   Implicit Bioscience
      2019   Phase 2   NCT03474263   Australia;United States;
IFB-088
   InFlectis BioScience
      2022   Phase 2   EUCTR2021-003875-32-IT   France;Italy;
IL-2
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom;
   Peking University Third Hospital
      2020   Phase 2   NCT04952155   China;
IL-2 per day
   Centre Hospitalier Universitaire de Nimes
      2015   Phase 2   NCT02059759   France;
ILB
   TikoMed AB
      2018   Phase 2   NCT03613571   Sweden;
      2018   Phase 2   EUCTR2017-005065-47-SE   Sweden;
   University of Birmingham
      2019   Phase 2   NCT03705390   United Kingdom;
ILB: 100mg/ml solution for injection and infusion
   University of Birmingham
      2018   Phase 2   EUCTR2018-000668-28-GB   United Kingdom;
IMMUNOGLOBULIN G
   Annexon Biosciences
      2021   Phase 2   EUCTR2021-000325-26-FR   Canada;France;United States;
INTERLEUKIN-2
   Nanjing Hospital Affiliated to Nanjing University of traditional Chinese Medicine
      2019   Phase 0   ChiCTR2000035966   China;
ION363
   IONIS PHARMACEUTICALS, INC.
      -   Phase 1;Phase 3   EUCTR2020-005522-28-IT   Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   NCT04768972   Belgium;Canada;United Kingdom;United States;
      -   Phase 1;Phase 2;Phase 3   EUCTR2020-005522-28-BE   Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
IPL344
   Immunity Pharma Ltd.
      2018   Phase 2   NCT03755167   Israel;
      2018   Phase 1/Phase 2   NCT03652805   Israel;
ISIS 333611
   Isis Pharmaceuticals
      2010   Phase 1   NCT01041222   United States;
Ibudilast
   MediciNova
      2016   Phase 1/Phase 2   NCT02714036   United States;
Icerguastat
   InFlectis BioScience
      2022   Phase 2   EUCTR2021-003875-32-IT   France;Italy;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Incobotulinum Toxin A
   Beth Israel Deaconess Medical Center
      2012   Phase 2   NCT01565395   United States;
Injection of salivary glands
   The University of Texas Health Science Center at San Antonio
      2003   Phase 2/Phase 3   NCT00125203   United States;
Inosine
   Massachusetts General Hospital
      2017   Phase 2   NCT03168711   United States;
      2015   Phase 1   NCT02288091   United States;
   Teikyo University
      2017   -   JPRN-UMIN000029308   Japan;
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Insulin like growth factor, type 1
   Mayo Clinic
      2003   Phase 3   NCT00035815   Puerto Rico;United States;
Intra venous injection of stem cell
   Royan Institute
      2013   Phase 1   NCT01759797   Iran, Islamic Republic of;
Intrathecal autologous stem cell
   Hospital Universitario Dr. Jose E. Gonzalez
      2012   Phase 2/Phase 3   NCT01933321   Mexico;
Intrathecal injection
   Royan Institute
      2013   Phase 1   NCT01771640   Iran, Islamic Republic of;
Intravenous administration of 1 million of MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain;
Intravenous administration of 2 million of MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain;
Intravenous administration of 4 million of MSC
   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
      2014   Phase 1/Phase 2   NCT02290886   Spain;
Intraventricular injection
   Royan Institute
      2014   Phase 1   NCT01759784   Iran, Islamic Republic of;
Ioflupane 123I
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2010   -   EUCTR2008-003982-21-FR   France;
Iowa Oral Performance Instrument
   University of Florida
      2017   -   NCT02962050   United States;
      2016   Early Phase 1   NCT02710162   United States;
Iowa Oral Pressure Instrument
   University of Florida
      2016   Early Phase 1   NCT02710110   United States;
Isocaloric Diet
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain;
Jevity 1.0
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States;
Jevity 1.5
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States;
KNS-760704
   Knopp Biosciences
      2009   Phase 2   NCT00931944   United States;
      2008   Phase 2   NCT00647296   United States;
Ketanest-S
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland;
KetoCal
   Johns Hopkins University
      2009   Phase 3   NCT01016522   United States;
L-Serine
   Elijah W. Stommel
      2018   Phase 2   NCT03580616   United States;
   Phoenix Neurological Associates, LTD
      2013   Phase 1/Phase 2   NCT01835782   United States;
LAM-002A
   AI Therapeutics, Inc.
      2021   Phase 2   NCT05163886   United States;
LIORESAL*50CPR
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy;
LITIO CARBONATO
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy;
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2009   -   EUCTR2008-006224-61-ES   Spain;
   Lucia Galan Hospital Clinico San Carlos
      2009   -   EUCTR2008-005106-38-ES   Spain;
Lacosamide
   Chiba University
      2017   Phase 1/Phase 2   NCT03186040   Japan;
   Department of Neurology Chiba University Hospital
      2017   -   JPRN-UMIN000027476   Japan;
   Kuwabara Satoshi
      2017   Phase 1-2   JPRN-jRCTs031180173   Japan;
Lactose
   FeGALS
      2009   -   JPRN-UMIN000008527   Japan;
Lamivudine
   Stichting TRICALS Foundation
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Netherlands;United Kingdom;
Lenograstim
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2005   -   EUCTR2005-003248-75-IT   Italy;
Lenzumestrocel
   Corestem, Inc.
      2021   Phase 3   NCT04745299   Korea, Republic of;
Leuprolide
   National Center for Research Resources (NCRR)
      1992   Phase 2   NCT00004771   -
Levetiracetam
   Duke University
      2006   Phase 2   NCT00324454   United States;
Levosimendan
   Orion Corporation, Orion Pharma
      2019   Phase 3   NCT03948178   Spain;
      2018   Phase 3   NCT03505021   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Lipoic acid group
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   -   NCT04518540   China;
Liposomed polyphenols resveratrol and curcumin
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2021   Phase 2   NCT04654689   Spain;
Lithium
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy;
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2008   -   EUCTR2008-001094-15-IT   Italy;
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT00925847   France;
   I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
      2007   -   EUCTR2007-002379-16-IT   Italy;
   ISTITUTO SUPERIORE DI SANITA`
      2009   -   EUCTR2008-006722-34-IT   Italy;
Lithium Apogepha
   King's College London
      2009   Phase 4   EUCTR2008-006891-31-GB   United Kingdom;
Lithium carbonate
   Forbes Norris MDA/ALS Research Center
      2008   Phase 2   NCT00790582   United States;
Lithiumcarbonaat 400 PCH tabletten
   Prof. dr L.H. van den Berg, UMC-Utrecht
      2008   -   EUCTR2008-002110-22-NL   Netherlands;
Lunasin Regimen
   Richard Bedlack, M.D., Ph.D.
      2016   Phase 2   NCT02709330   United States;
MANNITOLO LDB
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy;
MCI-186
   Mitsubishi Tanabe Pharma Corporation
      2007   Phase 3   NCT00424463   Japan;
      2006   Phase 3   NCT00415519   Japan;
      2006   Phase 3   NCT00330681   Japan;
MCI-186 in open label phase
   Mitsubishi Tanabe Pharma Corporation
      2011   Phase 3   NCT01492686   Japan;
MD1003
   MEDDAY PHARMACEUTICALS
      2016   Phase 2   EUCTR2015-005810-31-FR   France;
   MedDay Pharmaceuticals SA
      2016   Phase 2   NCT03114215   France;
MEMANTINE HYDROCHLORIDE
   Jorge Matias-Guiu Guia
      2008   -   EUCTR2007-002117-39-ES   Spain;
MN-166
   MediciNova
      2020   Phase 2/Phase 3   NCT04057898   Canada;United States;
      2014   Phase 2   NCT02238626   United States;
   MediciNova, Inc.
      2020   Phase 2;Phase 3   EUCTR2019-003549-14-HU   Germany;Greece;Hungary;Italy;Poland;Spain;United States;
MNC (Mononuclear cells)
   Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
      2021   Phase 2   NCT04849065   Spain;
   Red de Terapia Celular
      2014   Phase 1   NCT02286011   Spain;
MSC-NTF cells transplantation (IM)
   Brainstorm-Cell Therapeutics
      2011   Phase 1/Phase 2   NCT01051882   Israel;
MSC-NTF cells transplantation (IT)
   Brainstorm-Cell Therapeutics
      2011   Phase 1/Phase 2   NCT01051882   Israel;
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
   Brainstorm-Cell Therapeutics
      2012   Phase 2   NCT01777646   Israel;
MT-1186
   Mitsubishi Tanabe Development America Inc.
      2021   Phase 3   EUCTR2020-000376-38-IT   Canada;France;Germany;Italy;Japan;United States;
      2021   Phase 3   EUCTR2019-004256-11-IT   Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
      2020   Phase 3   EUCTR2019-002108-41-IT   Canada;France;Germany;Italy;Japan;United States;
   Mitsubishi Tanabe Pharma Corporation
      2020   Phase 1   NCT04254913   Japan;
      2019   Phase 1   NCT04176224   Japan;
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 3   EUCTR2020-000376-38-DE   Canada;France;Germany;Italy;Japan;United States;
      2020   Phase 3   NCT04577404   Canada;France;Germany;Italy;Japan;United States;
      2020   Phase 3   NCT04569084   Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
      2020   Phase 3   EUCTR2019-002108-41-DE   Canada;France;Germany;Italy;Japan;United States;
   Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
      2021   Phase 3   EUCTR2019-004256-11-DE   Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
MYELOSTIM 34*1FL 263MCG+1SIR
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2005   -   EUCTR2005-003248-75-IT   Italy;
MYONAL*30CPR RIV
   AZIENDA OSPEDALIERO-UNIVERSITARIA
      2010   -   EUCTR2010-020257-13-IT   Italy;
Masitinib (3.0)
   AB Science
      2013   Phase 2/Phase 3   NCT02588677   Spain;
Masitinib (4.5)
   AB Science
      2020   Phase 3   NCT03127267   Canada;Germany;United States;
      2013   Phase 2/Phase 3   NCT02588677   Spain;
Masitinib (6.0)
   AB Science
      2020   Phase 3   NCT03127267   Canada;Germany;United States;
Masitinib 100 mg Tablets
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib 200 mg Tablets
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib mesilate
   AB SCIENCE
      2021   Phase 3   EUCTR2019-001862-13-IT   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
Masitinib mesylate
   AB Science
      2022   Phase 3   EUCTR2019-001862-13-GR   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001862-13-DK   Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-PL   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
   ABScience
      2022   Phase 3   EUCTR2019-001862-13-PT   Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001862-13-NO   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-SI   Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-SE   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001862-13-ES   Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-PT   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-NL   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-HU   Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2010-024423-24-GR   Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2010-024423-24-SK   Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2010-024423-24-ES   France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
MediCabilis CBD Oil
   Gold Coast Hospital and Health Service
      2019   Phase 3   NCT03690791   Australia;
Medicine
   Center for iPS Cell Research and Application (CiRA), Kyoto University
      2019   Phase 1   JPRN-JMA-IIA00419   Japan;
Memantine
   Phoenix Neurological Associates, LTD
      2005   Phase 2   NCT01020331   United States;
   University of Alberta
      2007   Phase 2   NCT00409721   Canada;
   University of Kansas Medical Center
      2018   Phase 2   NCT02118727   United States;
Memantine (Ebixa)
   University of Lisbon
      2005   Phase 2/Phase 3   NCT00353665   Portugal;
Memantine Hydrochloride Oral Solution
   University of Edinburgh
      2020   Phase 2/Phase 3   NCT04302870   United Kingdom;
Mesenchymal stem cell
   Alzahra Hospital, Iran
      2015   Phase 1/Phase 2   NCT02116634   Iran, Islamic Republic of;
Mesenchymal stem cells
   Royan Institute
      2014   Phase 1   NCT02492516   Iran, Islamic Republic of;
Mesenchymal stem cells (MSC)
   Hadassah Medical Organization
      2016   Phase 1/Phase 2   NCT04821479   -
Mesenchymal stem cells isolated from Wharton's jelly
   Polski Bank Komorek Macierzystych JSC (PBKM)
      2020   Phase 1/Phase 2   NCT04651855   Poland;
Metformin
   University of Florida
      2020   Phase 2   NCT04220021   United States;
Methylcobalamin
   University of Tokushima
      2017   Phase 3   NCT03548311   Japan;
Methylphenylpyrazolone
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Methylprednisolone
   Emory University
      2013   Phase 2   NCT01884571   United States;
Mexiletine
   Bjorn Oskarsson, MD
      2013   Phase 4   NCT01811355   United States;
   Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
      2011   -   JPRN-UMIN000006423   Japan;
   University of Washington
      2016   Phase 2   NCT02781454   United States;
      2013   Phase 2   NCT01849770   United States;
Micro Mouth Pressure Meter
   University of Florida
      2016   Early Phase 1   NCT02710162   United States;
      2016   Early Phase 1   NCT02710110   United States;
Midazolam
   Genentech, Inc.
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States;
Minocycline
   Columbia University
      2006   Phase 2   NCT00355576   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2003   Phase 3   NCT00047723   United States;
Modal
   Oregon Health and Science University
      2021   -   NCT04468919   United States;
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
   The Methodist Hospital Research Institute
      2019   Phase 2   NCT04055623   United States;
Moxifloxacin
   Knopp Biosciences
      2012   Phase 1   NCT01511029   United States;
Multiple Dose
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom;
Mycophenolate mofetil
   Emory University
      2013   Phase 2   NCT01884571   United States;
NP001
   Neuraltus Pharmaceuticals, Inc.
      2016   Phase 2   NCT02794857   Canada;United States;
      2011   Phase 2   NCT01281631   United States;
      2010   Phase 1   NCT01091142   United States;
Norantipyrine
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Norphenazone
   Ferrer Internacional S.A.
      2021   Phase 3   EUCTR2020-003376-40-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Nuedexta
   Center for Neurologic Study, La Jolla, California,
      2013   Phase 2   NCT01806857   United States;
NurOwn® (MSC-NTF cells)
   Brainstorm-Cell Therapeutics
      2017   Phase 3   NCT03280056   United States;
ODM-109
   ORION CORPORATION ORION PHARMA
      2019   Phase 3   EUCTR2018-004180-31-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Orion Corporation
      2020   Phase 3   EUCTR2018-004180-31-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-DE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002754-36-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Orion Corporation, Orion Pharma
      2015   Phase 2   NCT02487407   Germany;Ireland;Netherlands;United Kingdom;
ODM-109 capsule
   Orion Corporation Orion Pharma
      2015   Phase 2   EUCTR2014-004567-21-NL   Germany;Ireland;Netherlands;United Kingdom;
      2015   Phase 2   EUCTR2014-004567-21-IE   Germany;Ireland;Netherlands;United Kingdom;
      2015   Phase 2   EUCTR2014-004567-21-GB   Germany;Ireland;Netherlands;United Kingdom;
      2015   Phase 2   EUCTR2014-004567-21-DE   Germany;Ireland;Netherlands;United Kingdom;
ONO-2506
   ONO PHARMA UK LTD
      2007   -   EUCTR2006-002660-26-IT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
ONO-2506PO
   ONO PHARMA UK LTD
      2004   -   EUCTR2004-002912-27-ES   Spain;
   ONO Pharmaceutical Co., Ltd.
      2008   Phase 2   EUCTR2007-004723-37-FR   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-GB   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-DE   Belgium;France;Germany;United Kingdom;
      2008   -   EUCTR2007-004723-37-BE   Belgium;France;Germany;United Kingdom;
   ONO Pharmaceutical Co.,Ltd
      2007   -   EUCTR2006-002660-26-NL   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2007   -   EUCTR2006-002660-26-GB   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   Phase 2   EUCTR2006-002660-26-FR   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-DE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-BE   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
      2006   -   EUCTR2006-002660-26-AT   Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
   Ono Pharmaceutical Co. Ltd
      2008   Phase 2   NCT00694941   Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
      2006   Phase 2   NCT00403104   Austria;Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
Olanzapine
   Charite University, Berlin, Germany
      2011   Phase 2/Phase 3   NCT00876772   Germany;
Olesoxime
   Hoffmann-La Roche
      2009   Phase 3   NCT00868166   Belgium;France;Germany;Netherlands;Spain;United Kingdom;
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom;
   TROPHOS SA
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom;
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom;
Oral LEVOSIMENDAN
   ORION CORPORATION ORION PHARMA
      2019   Phase 3   EUCTR2018-004180-31-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-IT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Orion Corporation
      2020   Phase 3   EUCTR2018-004180-31-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-DE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004180-31-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-002754-36-FR   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-NL   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-IE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-GB   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-FI   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-ES   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-BE   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002754-36-AT   Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Oral nutritional supplementation
   University Hospital, Limoges
      2014   -   NCT02152449   France;
Oxepa
   Massachusetts General Hospital
      2009   Phase 2   NCT00983983   United States;
Ozanezumab
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2012-003349-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
   GlaxoSmithKline
      2012   Phase 2   NCT01753076   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2012-003349-13-NL   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2013   -   EUCTR2012-003349-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-GB   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   Phase 2   EUCTR2012-003349-13-FR   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
      2012   -   EUCTR2012-003349-13-BE   Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
PARACETAMOLO
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy;
PBMC autotransplantation
   The First Affiliated Hospital of Dalian Medical University
      2010   -   NCT03085706   China;
PERFALGAN
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy;
PLENUR
   Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2009   -   EUCTR2008-006224-61-ES   Spain;
   Lucia Galan Hospital Clinico San Carlos
      2009   -   EUCTR2008-005106-38-ES   Spain;
PU-AD
   Samus Therapeutics, Inc.
      2021   Phase 2   NCT04505358   -
Pegcetacoplam
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2019-003797-10-IT   Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Pegcetacoplan (APL-2)
   Apellis Pharmaceuticals, Inc.
      2020   Phase 2   NCT04579666   Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Perampanel
   Department of Neurology, Juntendo University School of Medicine
      2017   Phase 1   JPRN-UMIN000026221   Japan;
   Department of Neurology, Tokyo Medical University
      2017   Phase 2   JPRN-UMIN000025614   Japan;
   Mayo Clinic
      2018   Early Phase 1   NCT03793868   United States;
   Stony Brook University
      2017   -   NCT03020797   United States;
   Tokyo Medical University
      2017   Phase 2   NCT03019419   Japan;
Phenylbutyrate
   Amylyx Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Pimozide 2 mg per day
   University of Calgary
      2015   Phase 2   NCT02463825   Canada;
Pimozide 2mg/day (current) or 4 mg/day (study initiation)
   University of Calgary
      2017   Phase 2   NCT03272503   Canada;
Pimozide 4 mg per day
   University of Calgary
      2015   Phase 2   NCT02463825   Canada;
Pioglitazone
   University Hospital of Ulm
      2008   -   EUCTR2006-005410-13-DE   Germany;
   University of Ulm
      2008   Phase 2   NCT00690118   Germany;Italy;
Pioglitazone and Tretinoin
   Phoenix Neurological Associates, LTD
      2008   Phase 1/Phase 2   NCT00919555   United States;
Plasma from healthy young people treatment + Riluzole
   Peking University Third Hospital
      2016   Early Phase 1   NCT04454840   China;
PolyMVA
   University of Missouri-Columbia
      2020   Phase 1   NCT04557410   United States;
PowerLung trainer
   University of Florida
      2016   Early Phase 1   NCT02710110   United States;
Prednisone
   Emory University
      2013   Phase 2   NCT01884571   United States;
Pridopidine
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04615923   United States;
      2020   Phase 2/Phase 3   NCT04297683   United States;
Probiotic
   Avera McKennan Hospital & University Health Center
      2017   -   NCT03324399   United States;
Proleukin 18 MUI
   CHU DE NIMES
      2016   Phase 2   EUCTR2015-005347-14-GB   United Kingdom;
Prototype capsule GDC-0134
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom;
Pulmonary Function Testing
   University of Florida
      2017   -   NCT02962050   United States;
      2016   Early Phase 1   NCT02710162   United States;
      2016   Early Phase 1   NCT02710110   United States;
Pyrimethamine
   Weill Medical College of Cornell University
      2009   Phase 1/Phase 2   NCT01083667   Germany;Italy;Sweden;United States;
Q-Cells
   Q Therapeutics, Inc.
      2021   Phase 1/Phase 2   NCT02478450   -
R(+) pramipexole dihydrochloride monohydrate
   Bennett, James P., Jr., M.D., Ph.D.
      2007   Phase 1/Phase 2   NCT00600873   United States;
      2005   Phase 1/Phase 2   NCT00140218   United States;
      2005   -   NCT00596115   -
RA15804589, C19061501-F, DNL788, DN2489, DN0002489
   Sanofi-aventis recherche & développement
      2022   Phase 2   EUCTR2021-004156-42-NL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-004156-42-ES   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-004156-42-BE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RAPA-501 Autologous T cells
   Rapa Therapeutics LLC
      2020   Phase 1/Phase 2   NCT04220190   United States;
RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
      2017   Phase 2   EUCTR2016-002399-28-IT   Italy;
RILUTEK 50 mg, film-coated tablets
   Aventis Pharma Ltd.
      2004   -   EUCTR2004-002390-23-DE   Germany;
RILUZOLO
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2016   Phase 2   EUCTR2014-005367-32-IT   Italy;
RNS60
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2017   Phase 2   EUCTR2016-002382-62-IT   Italy;United States;
   Mario Negri Institute for Pharmacological Research
      2016   Phase 2   NCT03456882   Italy;United States;
   Revalesio Corporation
      2022   Phase 2   NCT02988297   -
   Sabrina Paganoni, M.D.
      2015   Phase 1   NCT02525471   United States;
RT001
   Retrotope, Inc.
      2021   Phase 2   NCT04762589   Estonia;Latvia;Netherlands;Sweden;
      2021   Phase 2   EUCTR2020-003962-38-SE   Estonia;Netherlands;Sweden;
      2021   Phase 2   EUCTR2020-003962-38-NL   Estonia;Netherlands;Sweden;
      2021   Phase 2   EUCTR2020-003962-38-EE   Estonia;Netherlands;Sweden;
RYAH-Medtech Inhaler
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Rabeprazole
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom;
      2016   Phase 1   NCT02655614   Canada;Netherlands;United States;
Ranolazine
   University of Kansas Medical Center
      2018   Phase 2   NCT03472950   United States;
Rapamycin
   Azienda Ospedaliero-Universitaria di Modena
      2017   Phase 2   NCT03359538   Italy;
Rasagiline
   Richard Barohn, MD
      2013   Phase 2   NCT01786603   United States;
   University of Ulm
      2013   Phase 2   NCT01879241   Germany;
   Yunxia Wang, MD
      2011   Phase 2   NCT01232738   Canada;United States;
Ravulizumab
   Alexion Pharmaceuticals
      2020   Phase 3   NCT04248465   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Recombinant human erythropoietin(rhEPO)
   Hanyang University Seoul Hospital
      2016   Phase 1/Phase 2   NCT03835507   Korea, Republic of;
Reference capsule GDC-0134
   Genentech, Inc.
      2017   Phase 1   NCT03237741   United Kingdom;
Reldesemtiv
   CYTOKINETICS, INC.
      2021   Phase 3   EUCTR2020-004040-29-IT   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
   Cytokinetics
      2021   Phase 3   NCT04944784   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   NCT03160898   Australia;Canada;Ireland;Netherlands;Spain;United States;
   Cytokinetics, Inc.
      2018   Phase 2   EUCTR2018-000586-37-NL   Australia;Canada;Ireland;Netherlands;Spain;United States;
      2018   Phase 2   EUCTR2018-000586-37-IE   Australia;Canada;Ireland;Netherlands;Spain;United States;
      2018   Phase 2   EUCTR2018-000586-37-ES   Australia;Canada;Ireland;Netherlands;Spain;United States;
Repository corticotropin injection
   Mallinckrodt
      2013   Phase 2   NCT01906658   United States;
Requip CR tablets
   none
      2018   Phase 1-2   JPRN-JMA-IIA00397   Japan;
Rilutek
   Cytokinetics Inc
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Rilutek 50 mg film-coated tablets
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands;
Riluzole
   AB Science
      2020   Phase 3   NCT03127267   Canada;Germany;United States;
      2013   Phase 2/Phase 3   NCT02588677   Spain;
   AZIENDA OSPEDALIERA PISANA
      2009   -   EUCTR2009-010060-41-IT   Italy;
   Aventis Pharma Ltd.
      2004   -   EUCTR2004-002390-23-DE   Germany;
   Biohaven Pharmaceuticals, Inc.
      2018   -   NCT03537807   -
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom;
   Corestem, Inc.
      2021   Phase 3   NCT04745299   Korea, Republic of;
   Cytokinetics
      2012   Phase 2   NCT01709149   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2011   Phase 2   NCT01486849   United States;
   Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
      2011   -   JPRN-UMIN000006423   Japan;
   Guangdong Province Traditional Chinese Medical Hospital
      2014   -   ChiCTR-IOR-14005674   China;
   Hoffmann-La Roche
      2009   Phase 3   NCT00868166   Belgium;France;Germany;Netherlands;Spain;United Kingdom;
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03272802   Iran, Islamic Republic of;
   Massachusetts General Hospital
      2009   Phase 2/Phase 3   NCT00818389   Canada;United States;
   MediciNova
      2014   Phase 2   NCT02238626   United States;
   Peking University Third Hospital
      2021   Phase 2   ChiCTR2100044085   China;
   Sanofi
      2001   Phase 4   NCT00542412   Canada;
   Shanghai Sixth People's Hospital
      2020   Phase 0   ChiCTR2000035988   China;
   University Affiliated Sixth People's Hospital
      2021   Phase 0   ChiCTR2000028960   China;
   University of Lisbon
      2005   Phase 2/Phase 3   NCT00353665   Portugal;
   University of Roma La Sapienza
      2014   -   NCT02645461   -
Riluzole (100 mg)
   GENUV Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of;
Riluzole 50 MG (Part B)
   Cytokinetics
      2011   Phase 2   NCT01378676   United States;
Riluzole Oral Soluble Film
   Aquestive Therapeutics
      2018   Phase 2   NCT03457753   United States;
Riluzole Oral Soluble film (ROSF)
   Aquestive Therapeutics
      2018   Phase 2   NCT03679975   United States;
Riluzole tablet
   Peking University Third Hospital
      2020   Phase 2/Phase 3   NCT04950933   China;
Ritonavir
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States;
SAR443820
   Sanofi
      2022   Phase 2   NCT05237284   -
   Sanofi-aventis recherche & développement
      2022   Phase 2   EUCTR2021-004156-42-NL   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-004156-42-ES   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
      2022   Phase 2   EUCTR2021-004156-42-BE   Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
SB-509
   Sangamo Biosciences
      2008   Phase 2   NCT00748501   United States;
SLS-005
   Merit E. Cudkowicz, MD
      2022   Phase 2/Phase 3   NCT05136885   -
SLS-005 Trehalose
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04297683   United States;
SNN0029
   Newron Sweden AB
      2014   Phase 1   NCT01999803   Belgium;Netherlands;
      2009   Phase 1/Phase 2   NCT01384162   Belgium;
      2008   Phase 1/Phase 2   NCT00800501   Belgium;
SNN0029 infusion solution
   Newron Sweden AB
      2015   Phase 1   NCT02269436   Belgium;Netherlands;
SODIUM PYRUVATE
   Christoffer Laustsen
      2020   Phase 2   EUCTR2020-000352-36-DK   Denmark;
SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01160263   France;
SUB126308
   AB Science
      -   Phase 2;Phase 3   EUCTR2010-024423-24-IE   Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Saline solution
   University of Tokushima
      2017   Phase 3   NCT03548311   Japan;
Sativex
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2010-022808-40-IT   Italy;
Scopolamine
   Mie University Graduate school of medicine,Department of neurology
      2013   -   JPRN-UMIN000011494   Japan;
Scopolamine, atropine, edaravone and dexmedetomidine
   Ruijin Hospital
      2020   Phase 2   NCT04391361   China;
Selective Serotonin Uptake Inhibitors (SSRI)
   St. Louis University
      2015   Early Phase 1   NCT02851914   United States;
Single dose reduced
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom;
Single dose standard
   Knopp Biosciences
      2011   Phase 1   NCT01424163   United Kingdom;
Sodio phenylbutyrate
   AMYLYX PHARMACEUTICALS Inc.
      2021   Phase 3   EUCTR2021-000250-26-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Sodium Valproate
   UMC Utrecht
      2005   Phase 3   NCT00136110   Netherlands;
Sodium phenylbutyrate
   Department of Veterans Affairs
      2005   Phase 1/Phase 2   NCT00107770   United States;
Spirit1
   Herb Spirit
      2021   Phase 1   NCT02588807   Israel;
Stem Cell
   Neurogen Brain and Spine Institute
      2008   Phase 1   NCT02242071   India;
Stem Cells
   Stem Cells Arabia
      2016   Phase 1/Phase 2   NCT03067857   -
Stem cell
   Neurogen Brain and Spine Institute
      2008   Phase 2   NCT01984814   India;
Stem cell (HPC) implantation
   Cedars-Sinai Medical Center
      2017   Phase 1   NCT02943850   United States;
Stereotactic surgical device
   Cedars-Sinai Medical Center
      2017   Phase 1   NCT02943850   United States;
Suspension of human autologous MSC 3P in 1,5 ml
   Bioinova, s.r.o.
      2012   Phase 2   EUCTR2011-000362-35-CZ   Czech Republic;
Suspension of human autologous MSC 3P in 1.5 ml
   Bioinova, s.r.o.
      2012   Phase 1/Phase 2   NCT03828123   -
Synthetic stereopure antisense oligonucleotide targeting human C9orf72 hexanucleotide repeat-containing mRNA transcripts
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
TCH346
   NOVARTIS FARMA
      2004   -   EUCTR2004-002855-15-IT   Germany;Italy;United Kingdom;
   Novartis
      2004   Phase 2   NCT00230074   United States;
   Novartis Pharma Services AG
      2004   -   EUCTR2004-002855-15-GB   Germany;Italy;United Kingdom;
      2004   -   EUCTR2004-002855-15-DE   Germany;Italy;United Kingdom;
   Novartis Pharmaceuticals
      2003   Phase 2   NCT00072709   Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2002   Phase 2   NCT00036413   United States;
TEVAGRASTIM
   Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
      2014   Phase 2   EUCTR2014-002228-28-IT   Italy;
TJ-68
   Hiroshi Mitsumoto
      2021   Phase 1/Phase 2   NCT04998305   United States;
TPN-101
   Transposon Therapeutics, Inc
      2022   Phase 2   EUCTR2021-002251-11-ES   Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
TPN-101, 400 mg/day
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993755   France;United States;
TRO19622
   Hoffmann-La Roche
      2010   Phase 2/Phase 3   NCT01285583   Belgium;France;Germany;Spain;United Kingdom;
   TROPHOS
      2011   -   EUCTR2010-021179-10-GB   Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-GB   Belgium;France;Germany;Spain;United Kingdom;
   TROPHOS SA
      2011   Phase 2;Phase 3   EUCTR2010-021179-10-BE   Belgium;Germany;Spain;United Kingdom;
      2011   -   EUCTR2010-021179-10-DE   Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-FR   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-007320-25-BE   Belgium;France;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-007320-25-ES   Belgium;France;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-007320-25-DE   Belgium;France;Germany;Spain;United Kingdom;
TUDCA
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TUDCABIL
   Humanitas Mirasole SpA
      2019   Phase 3   EUCTR2018-002722-22-NL   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2019   Phase 3   EUCTR2018-002722-22-DE   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2019   Phase 3   EUCTR2018-002722-22-BE   Belgium;Germany;Italy;Netherlands;United Kingdom;
   IRCCS ISTITUTO CLINICO HUMANITAS
      2018   Phase 3   EUCTR2018-002722-22-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TV-7110
   Teva Pharmaceutical Industries, Ltd
      2008   Phase 2   EUCTR2008-002062-62-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   Phase 2   EUCTR2008-002062-62-ES   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tacrolimus
   Emory University
      2013   Phase 2   NCT01884571   United States;
Talampanel
   Teva Pharmaceutical Industries
      2009   Phase 2   NCT00982150   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
      2008   Phase 2   NCT00696332   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
   Teva Pharmaceutical Industries, Ltd
      2008   Phase 2   EUCTR2008-002062-62-FR   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   Phase 2   EUCTR2008-002062-62-ES   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
      2008   -   EUCTR2008-002062-62-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tallampanel
   Teva Pharmaceutical Industries,Ltd
      2008   -   EUCTR2008-002062-62-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tamoxifen
   Nazem Atassi
      2011   Phase 2   NCT01257581   United States;
   University of Wisconsin, Madison
      2001   Phase 2   NCT00214110   United States;
Tamoxifen 40 mg daily for one year
   Taipei Medical University Shuang Ho Hospital
      2014   Phase 1/Phase 2   NCT02166944   Taiwan;
Taurolite
   IRCCS ISTITUTO CLINICO HUMANITAS
      2019   Phase 3   EUCTR2018-002722-22-GB   Netherlands;United Kingdom;
Tauroursodeoxycholic acid
   IRCCS ISTITUTO CLINICO HUMANITAS
      2019   Phase 3   EUCTR2018-002722-22-GB   Netherlands;United Kingdom;
   ISTITUTO NEUROLOGICO CARLO BESTA
      2008   -   EUCTR2007-001592-10-IT   Italy;
Tauroursodeoxycholic acid (TUDCA)
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2008   Phase 2   NCT00877604   Italy;
Taurursodiol
   Amylyx Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Tenofovir alafenamide (TAF)
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1   NCT02437110   United States;
Testosterone
   National Center for Research Resources (NCRR)
      1992   Phase 2   NCT00004771   -
Thalidomide
   Dartmouth-Hitchcock Medical Center
      2005   Phase 2   NCT00140452   United States;
Thalidomide (drug)
   Charite University, Berlin, Germany
      2005   Phase 2   NCT00231140   Germany;
Theracurmin HP
   Richard Bedlack, M.D., Ph.D.
      2020   Phase 2   NCT04499963   United States;
Tioctic acid
   AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
      2006   -   EUCTR2005-005152-40-IT   Italy;
Tirasemtiv
   CYTOKINETICS, INC.
      2016   Phase 3   EUCTR2014-005413-23-IT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
   Cytokinetics
      2016   Phase 3   NCT02936635   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2015   Phase 3   NCT02496767   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
   Cytokinetics Inc
      2013   Phase 2   EUCTR2012-004987-23-GB   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-004987-23-ES   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-IE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-004987-23-DE   Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
      -   -   EUCTR2012-004987-23-NL   Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
   Cytokinetics, Inc.
      2017   Phase 3   EUCTR2016-002629-13-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-FR   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-ES   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002629-13-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-PT   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-NL   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-IE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-ES   Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-DE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005413-23-BE   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005413-23-GB   Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Tocilizumab
   Barrow Neurological Institute
      2015   Phase 2   NCT02469896   United States;
Tocotrienols
   University of Malaya
      2019   Phase 2   NCT04140136   Malaysia;
Tofersen
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2020-004590-51-IT   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Biogen Idec Research Limited
      2021   Phase 3   EUCTR2020-004590-51-FR   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004590-51-ES   Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004590-51-DE   Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2016-003225-41-ES   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2016-003225-41-DK   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2020   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DK   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-003225-41-DE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003225-41-BE   Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
      2016   Phase 1;Phase 2;Phase 3   EUCTR2015-004098-33-DE   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
Trametinib (0.5 mg)
   GENUV Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of;
Trametinib (1 mg)
   GENUV Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of;
Trametinib (2 mg)
   GENUV Inc.
      2020   Phase 1/Phase 2   NCT04326283   Korea, Republic of;
Trazodone Hydrochloride oral solution
   University of Edinburgh
      2020   Phase 2/Phase 3   NCT04302870   United Kingdom;
Tretinoin and Pioglitazone HCL
   Phoenix Neurological Associates, LTD
      2008   Phase 1/Phase 2   NCT00919555   United States;
Tricyclic Antidepressants (TCA)
   St. Louis University
      2015   Early Phase 1   NCT02851914   United States;
Triheptanoin
   Richard Bedlack, M.D., Ph.D.
      2018   Phase 1/Phase 2   NCT03506425   United States;
Trimetazidine
   The University of Queensland
      2021   Phase 2   EUCTR2020-005018-17-NL   Australia;Netherlands;
Trimetazidine Dihydrochloride
   The University of Queensland
      2021   Phase 2   NCT04788745   Australia;Netherlands;United Kingdom;
Triumeq
   Neuroscience Trials Australia
      2016   Phase 2   NCT02868580   Australia;
   Stichting TRICALS Foundation
      2021   Phase 3   EUCTR2020-005069-15-NL   Australia;Netherlands;United Kingdom;
Trobalt
   Centre for Human Drug Research
      2015   Phase 2   EUCTR2015-001431-20-NL   Netherlands;
Téralithe LP
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-003707-32-FR   France;
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-004619-30-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Alexion Pharmaceuticals
      2020   Phase 3   EUCTR2019-004619-30-SE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004619-30-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Ultra-high-caloric carbohydrate-rich diet
   Albert Christian Ludolph, Prof.
      2019   Phase 1   NCT04172792   Germany;
Ultra-high-caloric fatty diet
   Albert Christian Ludolph, Prof.
      2019   Phase 1   NCT04172792   Germany;
Umbilical cord blood therapy
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of;
Ursodoxicoltaurina
   Amylyx Pharmaceuticals Inc.
      2021   Phase 3   EUCTR2021-000250-26-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ursodoxicoltaurine
   Amylyx Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2021-000250-26-PL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-SE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000250-26-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
VM202
   Helixmith Co., Ltd.
      2014   Phase 1/Phase 2   NCT02039401   United States;
Vastarel
   The University of Queensland
      2021   Phase 2   EUCTR2020-005018-17-NL   Australia;Netherlands;
Verdiperstat
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04436510   United States;
      2020   Phase 2/Phase 3   NCT04297683   United States;
Videofluoroscopic Swallowing Study
   University of Florida
      2016   Early Phase 1   NCT02710162   United States;
Videofluoroscopic Swallowing Study (VFSS)
   University of Florida
      2017   -   NCT02962050   United States;
Videofluoroscopic swallowing study
   University of Florida
      2016   Early Phase 1   NCT02710110   United States;
Vitamin E
   Lawson Health Research Institute
      2006   Phase 3   NCT00372879   Canada;
Voluntary Peak Cough Flow Testing
   University of Florida
      2017   -   NCT02962050   United States;
WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS
   Polski Bank Komórek Macierzystych JSC (PBKM)
      2020   Phase 1;Phase 2   EUCTR2018-004171-12-PL   Poland;
WVE-004
   Wave Life Sciences Ltd.
      2021   Phase 1/Phase 2   NCT04931862   Australia;Canada;Ireland;Netherlands;United Kingdom;
   Wave Life Sciences UK Limited
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-SE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005193-94-BE   Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
Water
   Clinical Research Hospital Tokyo
      2014   -   JPRN-UMIN000015054   Japan;
   National Hospital Organization Takasaki General Medical Center
      2015   -   JPRN-UMIN000019111   Japan;
Withania somnifera
   Sunnybrook Health Sciences Centre
      2021   Phase 2   NCT05031351   -
YAM80
   Yoshino Neurology Clinic
      2009   Phase 2   NCT00886977   Japan;
ZIBREN*20BUST
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2005   -   EUCTR2004-004158-23-IT   Italy;
Zilucoplan
   Merit E. Cudkowicz, MD
      2020   Phase 2/Phase 3   NCT04436497   United States;
      2020   Phase 2/Phase 3   NCT04297683   United States;
Zinc and Copper
   Phoenix Neurological Associates, LTD
      2010   Phase 1/Phase 2   NCT01259050   United States;
Zyprexa
   Charité – Universitätsmedizin Berlin
      2008   -   EUCTR2007-003775-39-DE   Germany;
[11C]CPPC Injection
   Johns Hopkins University
      2021   Phase 1   NCT04749433   United States;
[11C]MPC6827
   Columbia University
      2021   Early Phase 1   NCT04575727   United States;
[18F] GE-180
   Massachusetts General Hospital
      2015   -   NCT02559869   United States;
[18F]DPA-714 PET
   University Hospital, Tours
      2015   Early Phase 1   NCT02405403   France;
[18F]PBR06
   Molecular NeuroImaging
      2016   Phase 1   NCT03876002   United States;
glatiramer acetate
   TEVA Pharmaceutical Industries. Ltd.
      2006   Phase 2   EUCTR2006-001688-49-GB   Belgium;Germany;Italy;United Kingdom;
      2006   -   EUCTR2006-001688-49-DE   Belgium;Germany;Italy;United Kingdom;
      2006   -   EUCTR2006-001688-49-BE   Belgium;Germany;Italy;United Kingdom;
   Teva Pharmaceutical Industries, Ltd.
      2006   Phase 2   NCT00326625   Belgium;France;Germany;Israel;Italy;United Kingdom;
glucose water solution
   Centre Hospitalier Universitaire de Nimes
      2017   Phase 2   NCT03039673   France;United Kingdom;